A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

Biochemical Journal

Volumn 438, Issue 1, 2011, Pages 53-62

  Jamieson, Stephen ^a,b   Flanagan, Jack U ^a,b   Kolekar, Sharada ^b   Buchanan, Christina ^b   Kendall, Jackie D ^a,b   Lee, Woo Jeong ^b   Rewcastle, Gordon W ^a,b   Denny, William A ^a,b   Singh, Ripudaman ^a   Dickson, James ^b   Baguley, Bruce C ^a,b   Shepherd, Peter R ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

p110 E545k mutation; Pan phosphoinositide 3 kinase (PI3K) mammalian target of rapamycin (mTOR) inhibitor NVP BEZ235; phosphoinositide 3 kinase (PI3K ); Phosphoinositide 4 kinase (PI4K); PIK3CA; PIK3CA H1047R mutation

Indexed keywords

INSULIN; P110 ALPHA PROTEIN; P110 BETA PROTEIN; P110 OMEGA PROTEIN; PHENMETRAZINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VIVO STUDY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; ENZYME INHIBITORS; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 79960794613     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20110502     Document Type: Article

References (55)

1. Shepherd, P. R., Withers, D. J. and Siddle, K. (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 333, 471-490 (Pubitemid 28398511)
2. Liu, P., Cheng, H., Roberts, T. M. and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644
3. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. and Bilanges, B. (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341
4. Navé, B. T., Haigh, R. J., Hayward, A. C., Siddle, K. and Shepherd, P. R. (1996) Compartment specific regulation of phosphoinositide 3-kinase by PDGF and insulin in 3T3-L1 adipocytes. Biochem. J. 318, 55-60
5. Navé, B. T., Siddle, K. and Shepherd, P. R. (1996) Phorbol ester stimulates phosphatidylinositol 3,4,5 tris phosphate production in 3T3-L1 adipocytes: implications for signalling to glucose transport. Biochem. J. 318, 203-205
6. Beeton, C. A., Chance, E. M., Foukas, L. C. and Shepherd, P. R. (2000) Comparison of the kinetic properties of the lipid and protein kinase activities of the p110α and p110β catalytic subunits of class Ia PI 3-kinases. Biochem. J. 350, 353-359
7. Leslie, N. R. and Downes, C. P. (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382, 1-11 (Pubitemid 39141560)
8. Chalhoub, N. and Baker, S. J. (2009) PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127-50
9. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (Pubitemid 38541907)
10. Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B. and Phillips, W. A. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681
11. Shayesteh, L., Lu, Y., Kuo, W., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B. and Gray, J. W. (1999) PI3KCA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99-102
12. Carson, J. D., Van Aller, G., Lehr, R., Sinnamon, R. H., Kirkpatrick, R. B., Auger, K. R., Dhanak, D., Copeland, R. A., Gontarek, R. R., Tummino, P. J. and Luo, L. (2008) Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem. J. 409, 519-524 (Pubitemid 351184970)
13. Chaussade, C., Cho, K., Mawson, C., Rewcastle, G. W. and Shepherd, P. R. (2009) Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem. Biophys. Res. Commun. 381, 577-581
14. Bader, A. G., Kang, S. and Vogt, P. K. (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 1475-1479
15. Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C. and Brugge, J. S. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65, 10992-11000 (Pubitemid 41713369)
16. Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W. et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573 (Pubitemid 40799249)
17. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356
18. Adams, J. R., Xu, K., Liu, J. C., Ruiz Agamez, N. M., Loch, A. J., Wong, R. G., Wang, W., Wright, K. L., Lane, T. F., Zacksenhaus, E. and Egan, S. E. (2011) Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 71, 2706-2717
19. Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C. H., Kinzler, K. W., Vogelstein, B. and Amzel, L. M. (2009) A frequent kinase domain mutation that changes the interaction between PI3Ka and the membrane. Proc. Natl. Acad. Sci. U.S.A. 106, 16996-17001
20. Miled, N., Yan, Y., Hon, W. C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M. and Williams, R. L. (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239-242
21. Pang, H., Flinn, R., Patsialou, A., Wyckoff, J., Roussos, E. T., Wu, H., Pozzuto, M., Goswami, S., Condeelis, J. S., Bresnick, A. R. et al. (2009) Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 69, 8868-8876
22. Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y. et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32
23. Zhao, L. and Vogt, P. K. (2010) Hot-spot mutations in p110a of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9, 596-600
24. Marone, R., Cmiljanovic, V., Giese, B. and Wymann, M. P. (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784, 159-185
25. Workman, P., Clarke, P. A., Raynaud, F. I. and van Montfort, R. L. (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 70, 2146-2157
26. Wee, S., Wiederschain, D., Maira, S. M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y. M. and Lengauer, C. (2008) PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U.S.A. 105, 13057-13062
27. Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L. et al. (2009) PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 69, 3955-62
28. Guerreiro, A. S., Fattet, S., Fischer, B., Shalaby, T., Jackson, S. P., Schoenwaelder, S. M., Grotzer, M. A., Delattre, O. and Arcaro, A. (2008) Targeting the PI3K p110a isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin. Cancer Res. 14, 6761-9
29. Haya kawa, M., Kawaguchi, K., Kaizawa, H., Koizumi, T., Ohishi, T., Yamano, M., Okada, M., Ohta, M., Tsukamoto, S., Raynaud, F. I. et al. (2007) Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110a inhibitors. Bioorg. Med. Chem. 15, 5837-5844
30. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B. et al. (2006) A pharmacological map of the PI3-K family defines a role for p110a in insulin signalling. Cell 125, 1-15
31. Chaussade, C., Rewcastle, G.W., Kendall, J. D., Denny, W. A., Cho, K., Gronning, L. M., Chong, M. L., Anagnostou, S. H., Jackson, S. P., Daniele, N. and Shepherd, P. R. (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem. J. 404, 449-458
32. Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A., Moasser, M., Weiss, W., Shokat, K. M. and Stokoe, D. (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem. J. 415, 97-110
33. Schmidt-Kittler, O., Zhu, J., Yang, J., Liu, G., Hendricks, W., Lengauer, C., Gabelli, S. B., Kinzler, K. W., Vogelstein, B., Huso, D. L. and Zhou, S. (2010) PI3Ka inhibitors that inhibit metastasis. Oncotarget 1, 339-348
34. Sun, M., Hillmann, P., Hofmann, B. T., Hart, J. R. and Vogt, P. K. (2010) Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110 α. Proc. Natl. Acad. Sci. U.S.A. 107, 15547-15552
35. Fairhurst, R. A. and Imbrich, P. (2009) Preparation of N1-bithiazolyl pyrrolidinedicarboxamides and related compounds as phosphatidylinositol 3-kinase inhibitors. PCT Int. Appl., WO 2009/080705
36. Chen, V. B., Arendall, 3rd, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 12-21
37. Falasca, M., Hughes, W. E., Dominguez, V., Sala, G., Fostira, F., Fang, M. Q., Cazzolli, R., Shepherd, P. R., James, D. E. and Maffucci, T. (2007) The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. Chem. 282, 28226-28236
38. Backer, J. M. (2008) The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J. 410, 1-17
39. Minogue, S., Waugh, M. G., De Matteis, M. A., Stephens, D. J., Berditchevski, F. and Hsuan, J. J. (2006) Phosphatidylinositol 4-kinase is required for endosomal trafficking and degradation of the EGF receptor. J. Cell Sci. 119, 571-580
40. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y. et al. (2005) PI 3-kinase p110β: a new target for antithrombotic therapy. Nat. Med. 11, 507-514
41. Balla, A., Tuymetova, G., Toth, B., Szentpetery, Z., Zhao, X., Knight, Z. A., Shokat, K., Steinbach, P. J. and Balla, T. (2008) Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry 47, 1599-1607 (Pubitemid 351231210)
42. Huang, C. H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B. and Amzel, L. M. (2007) The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 318, 1744-1748
43. Frazzetto, M., Suphioglu, C., Zhu, J., Schmidt-Kittler, O., Jennings, I. G., Cranmer, S. L., Jackson, S. P., Kinzler, K. W., Vogelstein, B. and Thompson, P. E. (2008) Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem. J. 414, 383-390
44. Sabbah, D. A., Vennerstrom, J. L. and Zhong, H. (2010) Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases. J. Chem. Inf. Model. 50, 1887-1898
45. Baguley, B. C., Marshall, E. S. and Finlay, G. J. (1999) Short-term cultures of clinical tumor material: potential contributions to oncology research. Oncol. Res. 11, 115-124
46. Kang, S., Denley, A., Vanhaesebroeck, B. and Vogt, P. K. (2006) Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 103, 1289-1294
47. Chen, H., Mei, L., Zhou, L., Shen, X., Guo, C., Zheng, Y., Zhu, H., Zhu, Y. and Huang, L. (2010) PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J. Neuro-oncol., doi:10.1007/s11060-010-0492-2
48. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M. and Zhao, J. J. (2008) Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454, 776-779
49. Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H. et al. (2008) Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci. Signaling 1, ra3
50. Edgar, K. A., Wallin, J. J., Berry, M., Lee, L. B., Prior, W. W., Sampath, D., Friedman, L. S. and Belvin, M. (2010) Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res. 70, 1164-1172
51. Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A. and Vanhaesebroeck, B. (2010) Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. U.S.A. 107, 11381-11386
52. Papakonstanti, E. A., Zwaenepoel, O., Bilancio, A., Burns, E., Nock, G. E., Houseman, B., Shokat, K., Ridley, A. J. and Vanhaesebroeck, B. (2008) Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J. Cell Sci. 121, 4124-4133
53. Yuan, T. L., Wulf, G., Burga, L. and Cantley, L. C. (2011) Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Curr. Biol. 21, 173-183
54. Zhao, L. and Vogt, P. (2008) Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 2652-2657
55. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chene, P., De Pover, A., Schoemaker, K. et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863